"We have cracked the code of atopic dermatitis [AD] disease pathology," Bola Akinlade, director of clinical sciences at Regeneron Pharmaceuticals Inc., told BioWorld Today, and with partner Sanofi SA the company is lined up to score what could be drug launch number three in as many years.